AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy Meeting Abstract


Authors: Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; Fleisher, M.; Lee, J.; Wang, Y.; Landers, M. A.; Dittamore, R. V.
Abstract Title: AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy
Meeting Title: 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 34
Issue: 15 Suppl.
Meeting Dates: 2016 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2016-05-20
Start Page: 269s
Language: English
ACCESSION: WOS:000404711500109
DOI: 10.1200/JCO.2016.34.15_suppl.5013
PROVIDER: wos
Notes: Meeting Abstract: 5013 -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Martin Fleisher
    303 Fleisher
  2. Howard Scher
    1081 Scher
  3. Jerry Seok Lee
    3 Lee